Holen Sie sich die Stockscreener-App
17.15
0.17%
-0.03
Handel nachbörslich:
17.15
Schlusskurs vom Vortag:
$17.18
Offen:
$17.17
24-Stunden-Volumen:
201.74K
Relative Volume:
0.44
Marktkapitalisierung:
$6.07B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-263.00M
KGV:
-22.17
EPS:
-0.7734
Netto-Cashflow:
$-167.84M
1W Leistung:
+1.36%
1M Leistung:
+5.93%
6M Leistung:
+38.31%
1J Leistung:
-4.56%
1-Tages-Spanne:
$17.00
$17.23
1-Wochen-Bereich:
$16.75
$17.23
52-Wochen-Spanne:
$10.45
$18.55
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.15 | 6.08B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
575.40 | 204.83B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
195.16 | 55.94B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.35 | 39.48B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
242.85 | 35.73B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
42.00 | 34.74B | 27.43B | 1.27B | 1.01B | 1.5829 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Does Bausch + Lomb’s Rising Focus on Eye Health Make Its Current Share Price Attractive? - simplywall.st
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
[8-K/A] Bausch & Lomb Corp Amends Material Event Report | BLCO SEC FilingForm 8-K/A - Stock Titan
Bausch + Lomb Corporation (NYSE:BLCO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Bausch + Lomb Corporation stock keep outperforming rivalsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Published on: 2025-12-18 17:17:15 - Улправда
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year - The Globe and Mail
Icahn Money Manager Sues His Bosses and Bausch + Lomb Over Anti-White Bias - Insurance Journal
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans - VisionMonday.com
Bausch + Lomb appoints two new directors to board effective January - Investing.com
Bausch + Lomb Adds New Directors to Board - TipRanks
Bausch & Lomb Corp Announces Board Appointments - TradingView — Track All Markets
Bausch + Lomb appoints two new directors to board effective January By Investing.com - Investing.com South Africa
Bausch + Lomb (NYSE: BLCO) appoints Eduardo Alfonso and Steven Collis to board - Stock Titan
Bausch + Lomb Brief: Appointing Eduardo C. Alfonso, and Steven H. Collis To Its Board, Effective Jan. 1, 2026; Board Will Then Be Comprised of 10 Directors - marketscreener.com
Bausch + Lomb Announces Two Board Of Directors Appointments - TradingView — Track All Markets
Leading eye specialist and Fortune 10 CEO join Bausch + Lomb board - Stock Titan
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year - The Motley Fool
Bausch + Lomb Corporation's (NYSE:BLCO) Prospects Need A Boost To Lift Shares - 富途牛牛
Large-Scale Debt Refinancing And Pipeline Optimism Might Change The Case For Investing In Bausch + Lomb (BLCO) - simplywall.st
(BLCO) Strategic Equity Report (BLCO:CA) - news.stocktradersdaily.com
America First Legal Files Lawsuit Against Bausch + Lomb for Racial Discrimination in Board Appointments - America First Legal
Bausch + Lomb: I Need To See Stability Before Upgrading This Name (BLCO) - Seeking Alpha
Nomura Holdings Inc. Cuts Holdings in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb (NYSE:BLCO) valuation after analyst upgrades highlight confidence in growth and margin improvement - simplywall.st
Bausch + Lomb allocates $2.8 bln in new term loans to refinance existing debt - MSN
How Bausch + Lomb’s $2.8 Billion Refi and Eye-Care Pipeline Momentum Will Impact Bausch + Lomb (BLCO) Investors - Yahoo Finance
(BLCO) Stock Trading Blueprint (BLCO:CA) - news.stocktradersdaily.com
Bausch + Lomb Announces $2.8 Billion Loan Refinancing - TipRanks
Bausch & Lomb Corp Announces Refinancing of Term B Loans - TradingView — Track All Markets
Bausch + Lomb allocates $2.8 billion to refinance outstanding loans By Investing.com - Investing.com South Africa
Bausch + Lomb allocates $2.8 billion to refinance outstanding loans - Investing.com
Bausch + Lomb (NYSE: BLCO) announces $2,802,125,000 term B refinancing with 2031 maturity - Stock Titan
Bausch + Lomb (NYSE: BLCO) allocates $2,802,125,000 term B loans at 3.75% - Stock Titan
Citi Upgrades Bausch + Lomb Corp.(BLCO.US) to Buy Rating, Announces Target Price $20 - 富途牛牛
Bausch + Lomb Shares Rise After Citigroup Upgrade - marketscreener.com
Why Bausch + Lomb (BLCO) Stock Is Trading Up Today - Finviz
Citigroup Upgrades Bausch + Lomb to Buy From Neutral, Adjusts Price Target to $20 From $16 - marketscreener.com
(BLCO) Market Insights and Trading Signals (BLCO:CA) - news.stocktradersdaily.com
Bausch + Lomb Corporation $BLCO Stock Holdings Raised by Goldentree Asset Management LP - MarketBeat
Arrowstreet Capital Limited Partnership Decreases Stock Holdings in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corporation (BLCO) - Minichart
How To Trade (BLCO) (BLCO:CA) - news.stocktradersdaily.com
Discipline and Rules-Based Execution in BLCO Response - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb Corpo - The National Law Review
(BLCO) Daily Stock Insights (BLCO:CA) - news.stocktradersdaily.com
Oaktree Capital Management LP Makes New Investment in Bausch + Lomb Corporation $BLCO - MarketBeat
Will Bausch + Lomb Corporation (S2L) stock see valuation expansionWeekly Stock Report & Risk Managed Investment Strategies - Newser
Is Bausch + Lomb Corporation (S2L) stock a defensive play amid uncertainty2025 EndofYear Setup & Trade Opportunity Analysis Reports - Newser
Is Bausch + Lomb Corporation (S2L) stock a fit for income portfoliosJuly 2025 Rallies & Low Drawdown Momentum Ideas - Newser
Wall Street Cautious on Bausch + Lomb Corporation (BLCO), Here's Why - Finviz
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):